EPS Bio Technology Corp. (4183) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of EPS Bio Technology Corp. stock TWD 6.02, price TWD 14.40, that is 58.2% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 12.45 TWD – 27.77 TWD · fair‑value band 4.71 TWD – 7.32 TWD · the 14.40 TWD price screens above the 6.02 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow EPS Bio Technology in your weekly email
Every Wednesday you see whether EPS Bio Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EPS Bio Technology Corp. manufactures and sells OEM/ODM blood glucose system in Taiwan. It also provides test strip; diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE name; and wearable, and NFC and Bluetooth connectivity blood glucose monitors.
Show moreShow less
The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.
Stock analysis
EPS Bio Technology Corp. (4183) currently trades at 14.40 TWD, while our model-based Fair Value estimate is 6.02 TWD, 58% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: 4.71 TWD (bear) to 7.32 TWD (bull), the price of 14.40 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
EPS Bio Technology Corp. reported revenue of 500M TWD in FY2025 versus 480M TWD in FY2021, a compound +1.0%/yr. Reported net income was −7.9M TWD in FY2025.
Key figures
Market cap 343M TWD (≈ $10.4M) Micro · P/S ratio 0.80 · EPS (TTM) −0.4200 TWD · Dividend yield 4.8% · Net margin −2.4% · Return on equity −3.6% · Return on assets (EBIT) 3.0% (5-year average) · Operating margin −0.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −58%, 4183 screens richer than that median.
Fair Value models
Bear4.71 TWDFair Value 6.02 TWDBull7.32 TWD
Price 14.40 TWD · Downside -58.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.13/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+10.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.1% (2020) → −1.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare EPS Bio Technology Corp. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−58.2% · Below median
Profitability
Return on assets−1.5% · Below median
Net margin (12 months)−2.4% · Below median
Operating margin (12 months)−0.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)−19.0% · Bottom 25%
Dividend yield (12 months)4.8% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B1.22× · Cheaper than median
P/S (12 months)0.82× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)0· sector 36
PAST (return on equity)0· sector 17
HEALTH (low debt)99· sector 98
DIVIDEND (yield)95· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "EPS Bio Technology Corp. Fair Value". https://www.fairvalue-calculator.com/stock/4183
Frequently asked questions
Is EPS Bio Technology Corp. (4183) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 6.02 TWD versus a price of 14.40 TWD, about 58% lower (overvalued).
What is the fair value of 4183?
Our model-based fair value for EPS Bio Technology Corp. is 6.02 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 14.40 TWD.
What is the quality score of 4183?
EPS Bio Technology Corp. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EPS Bio Technology Corp. (4183)?
Our model-based price target is the fair value of 6.02 TWD (as of Nov 4, 2026) from 2 valuation models. Cautious scenario 4.71 TWD, optimistic scenario 7.32 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the EPS Bio Technology Corp. stock forecast for 2026?
Our models put fair value at 6.02 TWD, about 58% lower versus a price of 14.40 TWD (overvalued). Cautious scenario 4.71 TWD, optimistic scenario 7.32 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of EPS Bio Technology Corp. (4183)?
EPS Bio Technology Corp. reported trailing-twelve-month revenue of about 419M TWD (latest available figure, as of Nov 4, 2026).
Does EPS Bio Technology Corp. pay a dividend?
EPS Bio Technology Corp. currently shows a dividend yield of 4.77% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of EPS Bio Technology Corp. (4183)?
EPS Bio Technology Corp. has a dividend yield of 4.8%.
What is the intrinsic value of EPS Bio Technology Corp. (4183)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EPS Bio Technology Corp. it is 6.02 TWD per share (as of Nov 4, 2026), against a price of 14.40 TWD. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is EPS Bio Technology Corp. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 4183 trades above its calculated fair value: price 14.40 TWD, fair value 6.02 TWD, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4183?
No. The price is what the market pays today (14.40 TWD); the fair value is what the company's own numbers justify (6.02 TWD). For EPS Bio Technology Corp. the two are 8.38 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is EPS Bio Technology Corp. worth?
The market values EPS Bio Technology Corp. at about 343M TWD (market capitalisation, as of Nov 4, 2026). Per share that is 14.40 TWD; our models calculate a fair value of 6.02 TWD per share.
What do the bullish and bearish scenarios say about 4183?
Our models span a range for EPS Bio Technology Corp.: cautious scenario 4.71 TWD, base 6.02 TWD, optimistic 7.32 TWD per share (as of Nov 4, 2026, price 14.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EPS Bio Technology Corp. (4183)?
Balance-sheet figures for EPS Bio Technology Corp. (as of Nov 4, 2026): return on equity −3.6%, debt of 0.03 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 4183 from its 52-week high?
EPS Bio Technology Corp. trades at 14.40 TWD, about 20% below its 52-week high of 18.00 TWD and 16% above the low of 12.45 TWD (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of 6.02 TWD is for.
Which stocks are comparable to EPS Bio Technology Corp.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EPS Bio Technology Corp. stock attractive at the current price?
The data as of Nov 4, 2026: price 14.40 TWD, calculated fair value 6.02 TWD (−58%), Quality Score 48/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4183 calculated?
We run EPS Bio Technology Corp. through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of 6.02 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. EPS Bio Technology Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EPS Bio Technology Corp. (4183)?
The closing price on Nov 5, 2026 was 14.40 TWD. Our model-based fair value is 6.02 TWD, about 58% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EPS Bio Technology Corp. right now?
The price sits above even our optimistic bull case (7.32 TWD). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of EPS Bio Technology Corp.
How large is the market capitalisation of EPS Bio Technology Corp. (4183)?
The market capitalisation of EPS Bio Technology Corp. is 343M TWD (≈ $10.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EPS Bio Technology Corp. (4183)?
The price-to-sales ratio of EPS Bio Technology Corp. is 0.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EPS Bio Technology Corp. (4183)?
Earnings per share at EPS Bio Technology Corp. are −0.4200 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of EPS Bio Technology Corp. (4183)?
The dividend yield of EPS Bio Technology Corp. is 4.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EPS Bio Technology Corp. (4183)?
The net margin of EPS Bio Technology Corp. is −2.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EPS Bio Technology Corp. (4183)?
The return on equity (ROE) of EPS Bio Technology Corp. is −3.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EPS Bio Technology Corp. (4183)?
On an EBIT basis the return on assets of EPS Bio Technology Corp. is 3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EPS Bio Technology Corp. (4183)?
The operating margin of EPS Bio Technology Corp. is −0.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EPS Bio Technology Corp. (4183)?
Revenue at EPS Bio Technology Corp. is growing −19.0% versus a year earlier (3y avg +2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does EPS Bio Technology Corp. (4183) generate?
The free cash flow of EPS Bio Technology Corp. is −23.4M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does EPS Bio Technology Corp. (4183) hold?
EPS Bio Technology Corp. holds more cash than debt, 18.8M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch EPS Bio Technology Corp. in the live analysis
One click puts EPS Bio Technology Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026